MedTrace Logo

Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

NCT04601701 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO) in comparison to Bevacizumab (Avastin) alone.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

Bevacizumab Ophthalmic and Intravitreal Dexamethasone.

Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.

DRUG

Bevacizumab Ophthalmic.

Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.

Sponsors & Collaborators

  • He Eye Hospital

    lead OTHER

Principal Investigators

  • Wei He, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

  • Jun Li, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

  • Emmanuel E Pazo, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2021-03-30
Completion
2021-09-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601701 on ClinicalTrials.gov